Eikon Therapeutics Inc.
Organization details
- Legal name
- Eikon Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Millbrae
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- EIKN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001861123
- EIN
- 84-2807586
Board of directors
-
David W. Meline · DirectorSince 2026
-
Josh Wolfe · DirectorSince 2026
-
Kenneth C. Frazier · DirectorSince 2026
-
Leon Chen · DirectorSince 2026
-
Ma. Fatima Francisco · DirectorSince 2026
-
Robert Luther Huffines · DirectorSince 2026
-
Roger M. Perlmutter · Director · See remarksSince 2026
Board connections
3 of this board's directors also sit on 5 other boards. 3 are in the same sector.
- via David W. Meline and Ma. Fatima Francisco
-
Becton Dickinson and Company Same sectorvia Robert Luther Huffines
-
Insulet Corporation Same sectorvia Robert Luther Huffines
-
Organon & Co. Same sectorvia Ma. Fatima Francisco
- via David W. Meline
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $52,150,756
- 10 purchases by 5 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 3, 2026 | Tim Kutzkey 10% owner | Open-market purchase | +89,200 | $11.56 | $1,031,152 |
| Feb 6, 2026 | Roger M. Perlmutter Director, Officer (See remarks) | Derivative conversion | +284,857 | — | — |
| Feb 6, 2026 | Column Group Opportunity III, LP 10% owner | Derivative conversion | +1,296,629 | — | — |
| Feb 6, 2026 | Column Group Opportunity III, LP 10% owner | Derivative conversion | +1,403,568 | — | — |
| Feb 6, 2026 | Column Group Opportunity III, LP 10% owner | Derivative conversion | +110,928 | — | — |
| Feb 6, 2026 | Josh Wolfe Director, 10% owner | Derivative conversion | +2,387,705 | — | — |
| Feb 6, 2026 | Josh Wolfe Director, 10% owner | Derivative conversion | +2,387,705 | — | — |
| Feb 6, 2026 | Column Group Opportunity III, LP 10% owner | Derivative conversion | +44,249 | — | — |
| Feb 6, 2026 | Josh Wolfe Director, 10% owner | Derivative conversion | +1,151,540 | — | — |
| Feb 6, 2026 | Josh Wolfe Director, 10% owner | Derivative conversion | +1,151,540 | — | — |
| Feb 6, 2026 | Column Group Opportunity III, LP 10% owner | Derivative conversion | +47,898 | — | — |
| Feb 6, 2026 | Josh Wolfe Director, 10% owner | Derivative conversion | +2,155,765 | — | — |
| Feb 6, 2026 | Josh Wolfe Director, 10% owner | Derivative conversion | +2,155,765 | — | — |
| Feb 6, 2026 | Column Group Opportunity III, LP 10% owner | Derivative conversion | +3,785 | — | — |
| Feb 6, 2026 | Column Group Opportunity III, LP 10% owner | Derivative conversion | +688,283 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Eikon Therapeutics Inc.
How many directors are on Eikon Therapeutics Inc.'s board?
Eikon Therapeutics Inc.'s board has 7 directors: David W. Meline, Josh Wolfe, Kenneth C. Frazier, Leon Chen, Ma. Fatima Francisco, Robert Luther Huffines and Roger M. Perlmutter.
Are Eikon Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Eikon Therapeutics Inc. insiders bought $52.2 million of shares in 10 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="eikon-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.